Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf101 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Oncologist, online erschienen am 12.06.2025. Verfasst von Lichen Tang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Shanghai, People's Republic of…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Cancer Hospital, Fudan University.
Abstract (Originalsprache)
Background
Pegylated liposomal doxorubicin (PLD) was shown to have comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity. This study evaluated the cardiotoxicity and efficacy of the PLD-based regimen compared with those of the doxorubicin-based regimen as adjuvant therapy for early-stage breast cancer (BC).
Methods
In this open-label, randomized controlled trial, patients with early-stage BC were assigned to receive either 4 cycles of PLD (study group) or doxorubicin (control group) plus cyclophosphamide followed by 4 cycles of docetaxel/paclitaxel. The primary endpoint was cardiotoxicity.
Results
Between November 2017 and September 2019, 247 patients (study group, n = 131; control group, n = 116) were enrolled. Incidence rates of abnormal left ventricular ejection fraction (LVEF, 0 vs. 1.7%) and congestive heart failure (0.0% vs. 0.9%) were similar between the two groups (all P > 0.05). A lower proportion of elevated high-sensitivity cardiac troponin T (3.8% vs. 30.2%, P < 0.001) was observed in the study group. The 5-year disease-free survival (82.7% vs. 83.8%) and overall survival (90.4% vs. 91.6%) rates were comparable (all P > 0.05). Grade 3-4 adverse events in the study group were significantly less than in the control group (43.5% vs. 61.2%, P = 0.005).
Conclusion
The PLD-based regimen for early-stage BC showed significantly lower rates of elevated hs-cTnT and grade 3-4 AEs with comparable efficacy to the doxorubicin-based regimen. (ClinicalTrials.gov Identifier: NCT03949634; IRB Approved: Ethics committee institutional review board of Shanghai Cancer Hospital, Fudan University’s (No. 1706173-19-1904B) and other center).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Shanghai, People's Republic of China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
- Department of Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- Department of Breast Surgery, Bethune First Hospital of Jilin University, Changchun, People's Republic of China.
- Department of Thyroid and Breast surgery, Xijing Hospital of Air Force Military Medical University, Xi'an, People's Republic of China.
- Department of Breast Surgery, Yantai Yuhuangding Hospital, Yantai, People's Republic of China.
ORCID-Profile: Guangdong Qiao, Zhonghua Wang
Förderung
- Shanghai Cancer Hospital, Fudan University
Zitieren
APA
Tang, L., He, M., Geng, C., Fan, Z., Ling, R., Qiao, G., Cai, L., Luo, T., Jin, F., Wang, H., Zhang, A., Zhang, H., Zeng, X., Wang, X., Jiang, M., Wang, Z., & Shao, Z. (2025). Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf101
Vancouver
Tang L, He M, Geng C, Fan Z, Ling R, Qiao G, et al. Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf101
BibTeX
@article{Tang2025,
author = {Tang, Lichen and He, Min and Geng, Cuizhi and Fan, Zhimin and Ling, Rui and Qiao, Guangdong and Cai, Li and Luo, Ting and Jin, Feng and Wang, Haibo and Zhang, Anqin and Zhang, Hongwei and Zeng, Xiaohua and Wang, Xiaojia and Jiang, Ming and Wang, Zhonghua and Shao, Zhimin},
title = {Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf101}
}
EUVIMED